RAVEN reviewed source reporting
U.S. · Health
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
Originally published by U.S. Food and Drug Administration ·
The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT).
Source provenance
- Source
- U.S. Food and Drug Administration
- Issuing body
- U.S. Food and Drug Administration
- RAVEN publication
- Human-reviewed source selection
Share this page
RAVEN loads no social-media scripts or tracking pixels on this page. A social platform is contacted only after you choose it.